Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» What You May Have Missed in Biotech: Cholesterol Drug Scrutiny and a Hedge Fund Alzheimer's Play
What You May Have Missed in Biotech: Cholesterol Drug Scrutiny and a Hedge Fund Alzheimer's Play
What You May Have Missed in Biotech: Cholesterol Drug Scrutiny and a Hedge Fund Alzheimer's Play
Submitted by
admin
on June 13, 2015 - 10:36am
Source:
Forbes
News Tags:
biotech
GSK
Axovant Sciences
Alzheimer's disease
PCSK9 inhibitors
Praluent
Sanofi
Regeneron
Repatha
Amgen
Headline:
What You May Have Missed in Biotech: Cholesterol Drug Scrutiny and a Hedge Fund Alzheimer's Play
Do Not Allow Advertisers to Use My Personal information
